CRISPR/Cas9-Mediated Re-Sensitization of Antibiotic-Resistant Escherichia coli Harboring Extended-Spectrum β-Lactamases
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (CRISPR/Cas9) system, a genome editing technology, was shown to be versatile in treating several antibiotic-resistant bacteria. In the present study, we applied the CRISPR/ Cas9 technology to kill extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. ESBL bacteria are mostly multidrug resistant (MDR), and have plasmid-mediated antibiotic resistance genes that can be easily transferred to other members of the bacterial community by horizontal gene transfer. To restore sensitivity to antibiotics in these bacteria, we searched for a CRISPR/Cas9 target sequence that was conserved among >1,000 ESBL mutants. There was only one target sequence for each TEM- and SHV-type ESBL, with each of these sequences found in ~200 ESBL strains of each type. Furthermore, we showed that these target sequences can be exploited to re-sensitize MDR cells in which resistance is mediated by genes that are not the target of the CRISPR/Cas9 system, but by genes that are present on the same plasmid as target genes. We believe our Re-Sensitization to Antibiotics from Resistance (ReSAFR) technology, which enhances the practical value of the CRISPR/Cas9 system, will be an effective method of treatment against plasmid-carrying MDR bacteria.
Abstract
Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (CRISPR/Cas9) system, a genome editing technology, was shown to be versatile in treating several antibiotic-resistant bacteria. In the present study, we applied the CRISPR/ Cas9 technology to kill extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. ESBL bacteria are mostly multidrug resistant (MDR), and have plasmid-mediated antibiotic resistance genes that can be easily transferred to other members of the bacterial community by horizontal gene transfer. To restore sensitivity to antibiotics in these bacteria, we searched for a CRISPR/Cas9 target sequence that was conserved among >1,000 ESBL mutants. There was only one target sequence for each TEM- and SHV-type ESBL, with each of these sequences found in ~200 ESBL strains of each type. Furthermore, we showed that these target sequences can be exploited to re-sensitize MDR cells in which resistance is mediated by genes that are not the target of the CRISPR/Cas9 system, but by genes that are present on the same plasmid as target genes. We believe our Re-Sensitization to Antibiotics from Resistance (ReSAFR) technology, which enhances the practical value of the CRISPR/Cas9 system, will be an effective method of treatment against plasmid-carrying MDR bacteria.
참고문헌 (24)
- Abraham EP, "An enzyme from bacteria able to destroy penicillin", Rev. Infect. Dis, 10, pp.677~678 (1940)
- Bhaya D, "CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation", Annu. Rev. Genet, 45, pp.273~297 (2011)
- Bikard D, "Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials", Nat. Biotechnol, 32, pp.1146~1150 (2014)
- Butler MS, "Antibiotics in the clinical pipeline in 2013", J. Antibiot, 66, pp.571~591 (2013)
- Citorik RJ, "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases", Nat. Biotechnol, 32, pp.1141~1145 (2014)
- Cong L, "Multiplex genome engineering using CRISPR", Cas systems, 2013, pp.339, 819~823
- Fleming A, "On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzæ", Br. J. Exp. Pathol, 10, pp.226~236 (1929)
- Jiang W, "RNA-guided editing of bacterial genomes using CRISPRCas systems", Nat. Biotechnol, 31, pp.233~239 (2013)
- Jinek M, "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", Science, 337, pp.816~821 (2012)
- Jones CH, "Characterization and sequence analysis of extendedspectrum-b-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials", Antimicrob. Agents Chemother, 53, pp.465~475 (2009)
- Kaur M, "Occurrence of the CTX-M, SHV and the TEM genes among the extended spectrum betalactamase producing isolates of Enterobacteriaceae in a tertiary care hospital of North India", J. Clin. Diagn. Res, 7, pp.642~645 (2013)
- Knothe H, "Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens", Infection, 11, pp.315~317 (1983)
- Lew W, "Initial drug resistance and tuberculosis treatment outcomes:systematic review and meta-analysis", Ann. Intern. Med, 149, pp.123~134 (2008)
- Paterson DL, "Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extendedspectrum beta-lactamases (ESBLs)", Clin. Microbiol. Infect, 6, pp.460~463 (2000)
- Paterson DL, "Extended-spectrum betalactamases:a clinical update", Clin. Microbiol. Rev, 18, pp.657~686 (2005)
- Rawat D, "Extended-spectrum beta-lactamases in gram-negative bacteria", J. Global Infect. Dis, 2, pp.263~274 (2010)
- Sanders CC, "Emergence of resistance to cefamandole: possible role of cefoxitin-inducible betalactamases", Antimicrob. Agents Chemother, 15, pp.792~797 (1979)
- Tissera S, "Isolation of extended spectrum beta-lactamase (ESBL) producing bacteria from urban surface waters in Malaysia", Malays. J. Med. Sci, 20, pp.14~22 (2013)
- van der Oost J, "Unravelling the structural and mechanistic basis of CRISPRCas systems", Nat. Rev. Microbiol, 12, pp.479~492 (2014)
- Walsh CT, "Prospects for new antibiotics: a molecule-centered perspective", J. Antibiot, 67, pp.7~22 (2014)
- Wiedenheft B, "RNA-guided genetic silencing systems in bacteria and archaea", Nature, 482, pp.331~338 (2012)
- Wise R, "Antimicrobial resistance: priorities for action", J. Antimicrob. Chemother, 49, pp.585~586 (2002)
- Woodford N, "Infections caused by gram-positive bacteria: a review of the global challenge", J . Infect, 59(Suppl 1), pp.S4~S16 (2009)
- Yosef I, "Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria", Proc. Natl. Acad. Sci. USA, 112, pp.7267~7272 (2015)